Clinical Trial

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
This decision is based solely on internal company prioritization and resource allocation considerations. No patients have been enrolled or dosed in this study and no clinical data have been generated.
Summary
This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Withdrawn 2026-04-14
notable Enrollment reduced: 90 -> 0 participants 2026-04-14
Trial Details
NCT Number NCT07255846
Lead Sponsor Terremoto Biosciences Inc.
Conditions Hereditary Hemorrhagic Telangiectasia (HHT)
Start Date 2025-12-15
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-04-13